AIM: To investigate whether SV2A loss spreads from brainstem to cerebral cortex with progression of Parkinson's disease (PD) and to determine whether longitudinal cortical SV2A loss correlates with cognitive decline in PD. STUDY DESIGN: The investigators will re-invite participants (both patients with PD and healthy controls) of a previous longitudinal study (NCT04243304, S61477) to undergo evaluation approximately 7 years after the initial baseline study visit (i.e. on average 10 years since the first motor symptoms). All participants will undergo clinical assessment of motor and non-motor symptoms (including cognitive testing), as well as 11C-UCB-J PET-CT (targeting synaptic density marker SV2A), 18F-FE-PE2I PET-CT (targeting DAT) and brain MRI.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
35
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I.
Magnetic resonance imaging of brain volume.
UZ Leuven
Leuven, Belgium
RECRUITINGCross-sectional SV2A at Year 7
Cross-sectional differences (%) in SV2A signal at Year 7 between Parkinson disease patients and controls.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Cross-sectional correlation between clinical scores and SV2A at Year 7
Cross-sectional correlation between clinical scores and SV2A in Parkinson disease patients at Year 7.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Longitudinal SV2A change between baseline and Year 7
Differences (%) in the rate of SV2A change between baseline and Year 7 between Parkinson disease patients and controls.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Longitudinal correlation between clinical scores and SV2A
Correlation between progression of the clinical scores and longitudinal SV2A changes in Parkinson disease patients.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Cross-sectional DAT levels at Year 7
Cross-sectional differences (%) in DAT levels at Year 7 between Parkinson disease patients and controls.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Cross-sectional correlation between clinical scores and DAT levels at Year 7
Cross-sectional correlation between clinical scores and DAT levels in Parkinson disease patients at Year 7.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Longitudinal DAT level change between baseline and Year 7
Differences (%) in the rate of DAT level change between baseline and Year 7 between Parkinson disease patients and controls.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Longitudinal correlation between clinical scores and DAT levels
Correlation between progression of the clinical scores and longitudinal DAT level changes in Parkinson disease patients.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
Longitudinal correlation between SV2A and DAT levels
Correlation between SV2A changes and DAT level changes in Parkinson disease patients.
Time frame: Data analysis will be done when all subjects have undergone Year 7 evaluation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.